readthroughSign in
Nov 3, 2026Trial update

BeOne Medicines registers Phase 2 trial of BGB-B2033 in pretreated liver cancer

The study will test the GPC3-targeting drug in hepatocellular carcinoma patients who progressed on or could not tolerate prior PD-1/PD-L1 therapy.

BeOne Medicines registered one new study this week.

  • BGB-B2033, an experimental drug that attaches to glypican-3 (GPC3), a protein found on the surface of many liver cancer cells, and also binds to cells of the immune system, helping the immune system to recognize and attack the cancer cells1, is the subject of a Phase 2 single-arm study (NCT07911683, status: not yet recruiting). Eligible participants must have documented disease progression or intolerance after at least one prior line of systemic therapy containing an anti-PD-1 or anti-PD-L1 therapy1, and the trial plans to enroll approximately 100 adults at multiple centers worldwide with hepatocellular carcinoma that cannot be treated with curative surgery or local treatments, or that has progressed after surgery or local treatment1.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.